PRMT5-IN-57
PRMT5-IN-57 is an orally active andselective MTA-cooperative PRMT5 inhibitor, with an IC50 of 8.39 nM against PRMT5/MTA complex. PRMT5-IN-57 exhibits potent and selective antiproliferative activity against MTAP-null cancer cells. PRMT5-IN-57 demonstrates significant in vivo antitumor efficacy in an HCT116 MTAP-/- CDX model. PRMT5-IN-57 can be used for the research of MTAP-deleted cancers.
For research use only. We do not sell to patients.
- CAS No.: 3064280-41-4
- Formula: C27H23FN8O
- Molecular Weight:494.52
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Histone Methyltransferase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
PRMT5 8.39 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SK-HEP1 | IC50 |
3 nM
|
Exhibits potent antiproliferative activity against SK-HEP-1 cells.
Exhibits potent antiproliferative activity against SK-HEP-1 cells.
|
42305212 |
| NCI-H1650 | IC50 |
5 nM
|
Exhibits potent antiproliferative activity against NCI-H1650 cells.
Exhibits potent antiproliferative activity against NCI-H1650 cells.
|
42305212 |
| HCT116 MTAP-de | IC50 |
6.4 nM
|
Exhibits potent antiproliferative activity against HCT116 MTAP-del cells.
Exhibits potent antiproliferative activity against HCT116 MTAP-del cells.
|
42305212 |
In Vitro
PRMT5-IN-57 (Compound 27; up to 20 μM; 10 days) exhibits potent antiproliferative activity against MTAP-null cancer cells, with IC50 values of 6.4 nM (HCT116 MTAP-del), 5.0 nM (NCI-H1650), and 3.0 nM (SK-HEP-1), showing 102-, 392-, and 168-fold selectivity over their respective MTAP-WT counterparts [1].
PRMT5-IN-57 (10 min preincubation + 180 min reaction) shows potent PRMT5/MTA enzyme inhibition with an IC50 of 8.39 nM in the MTase-Glo assay[1].
PRMT5-IN-57 (3-6 nM; 4 days) reduces SDMA levels in MTAP-null cells (HCT116 MTAP-/-, NCI-H1650, and SK-HEP-1) while showing minimal effect on MTAP-WT cells (HCT116 WT, Calu-1, and HepG2) at the same concentrations, as determined by Western blot analysis[1].
PRMT5-IN-57 (10 μM) shows no inhibitory effect on CYP3A4-midazolam and CYP3A4-testosterone in human liver microsomes[1].
PRMT5-IN-57 (IC5010 μM) exhibits minimal inhibition of the hERG potassium channel in the PredictorTM hERG Fluorescence Polarization Assay[1].
PRMT5-IN-57 demonstrates high metabolic stability in mouse, rat, and human liver microsomes, with half-lives (T1/2) of 38.5 min, 39.1 min, and 49.6 min, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCT116 MTAP-/-, NCI-H1650, SK-HEP-1 (MTAP-null); HCT116 WT, Calu-1, HepG2 (MTAP-WT) cells
-
Concentration:6 nM (HCT116 WT & MTAP-/-), 5 nM (NCI-H1650 & Calu-1), 3 nM (SK-HEP-1 & HepG2)
-
Incubation Time:4 days
-
Result:Reduced SDMA levels in MTAP-null cells while showing minimal effect on MTAP-WT cells.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c nude mice (6-8 weeks old, 17-20 g) were subcutaneously injected with 0.1 mL of a suspension containing 1 × 107 HCT116 MTAP-/- cells (1 × 108 cells/mL in serum-free McCoy's 5A medium) into the left axilla[1].
-
Dosage:50 mg/kg
-
Administration:Oral gavage (p.o.); once daily; 21 days (starting when tumors reached a mean volume of approximately 150 mm3)
-
Result:Significantly suppressed tumor growth with a tumor growth inhibition (TGI) of 74% and a mean tumor volume of 348 mm3 at the study endpoint, compared to 1362 mm3 in the vehicle group.
Reduced mean tumor weight to 0.24 g, compared to 1.04 g in the vehicle group and 0.39 g in the MRTX1719 group.
Demonstrated superior antitumor efficacy compared to the clinical benchmark MRTX1719 at the same dose, which achieved 63% TGI.
No significant body weight loss was observed.
Chemical Information
-
CAS No. 3064280-41-4
-
Molecular Weight 494.52
-
Formula C27H23FN8O
-
SMILES
CN1C=C(C=N1)C#CC2=CC=C(N=C2)CN(C3CC3)C(C4=C(C=C5N=C(C6=C(N(N=C6)C)C5=C4)N)F)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)